CalciMedica (NASDAQ:CALC) Director Buys $199,177.60 in Stock

CalciMedica Inc. (NASDAQ:CALC) Director Fred Middleton purchased 248,972 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was acquired at an average cost of $0.80 per share, for a total transaction of $199,177.60. Following the completion of the acquisition, the director owned 1,063,272 shares in the company, valued at $850,617.60. This represents a 30.57% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

CalciMedica Stock Performance

CALC opened at $1.04 on Thursday. The company has a fifty day moving average of $0.74 and a 200 day moving average of $1.85. CalciMedica Inc. has a fifty-two week low of $0.46 and a fifty-two week high of $7.20. The stock has a market capitalization of $16.43 million, a price-to-earnings ratio of -0.79 and a beta of 0.88.

Institutional Investors Weigh In On CalciMedica

A number of large investors have recently modified their holdings of CALC. 180 Wealth Advisors LLC raised its holdings in shares of CalciMedica by 297.2% in the first quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock worth $68,000 after buying an additional 94,650 shares during the last quarter. Boothbay Fund Management LLC acquired a new position in shares of CalciMedica in the 4th quarter valued at $506,000. PVG Asset Management Corp purchased a new position in CalciMedica in the 4th quarter worth $302,000. Renaissance Technologies LLC raised its stake in CalciMedica by 45.0% in the 1st quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock worth $69,000 after acquiring an additional 39,775 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its position in CalciMedica by 58.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after acquiring an additional 34,386 shares during the period.

Analyst Upgrades and Downgrades

Separately, Oppenheimer reduced their price target on shares of CalciMedica from $20.00 to $10.00 and set an “outperform” rating for the company in a report on Thursday, March 5th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $10.00.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.